The purpose of this study was to determine the effect of supplementing the diet of a mouse 24 model of type 2 diabetes with menhaden (fish) oil or daily treatment with resolvin D1 on diabetic 25 neuropathy. The endpoints evaluated included motor and sensory nerve conduction velocity, 26 thermal sensitivity, innervation of sensory nerves in the cornea and skin and the retinal ganglion 27 cell complex thickness. Menhaden oil is a natural source for n-3 polyunsaturated fatty acids, 28 which have been shown to have beneficial effects in other diseases. Resolvin D1 is a 29 metabolite of docosahexaenoic acid, and is known to have anti-inflammatory and 30 neuroprotective properties. To model type 2 diabetes mice were fed a high fat diet for 8 weeks 31
Serum samples were collected for determination of free fatty acid, triglyceride, free cholesterol 159 and resolvin D1 using commercial kits from Roche Diagnostics, Mannheim, Germany; Sigma-160 Aldrich Co., St. Louis, MO; BioVision, Mountain View, CA; and Cayman Chemical Co., Ann 161
Arbor, MI respectively. Fatty acid composition of the diets was determined by gas-liquid 162 chromatography. Lipids were extracted from diets with a 2:1 (vol/vol) mixture of chloroform and 163 methanol followed by phase separation with a solution of 154 mM NaCl and 4 mM HCl. Fatty 164 acid composition were measured after the lipid fraction was trans esterified in 14% boron 165 trifluoride in methanol and the fatty acid methyl esters extracted into heptane before separation 166 by gas-liquid chromatography (Yorek et al. 1984) . Individual fatty acids peaks as % of total fatty 167 acids present were identified by comparison to known fatty acid standards. 168
Adult mouse sensory neuron culture: Adult mouse sensory neurons were isolated from 169 dorsal root ganglia (DRG) and grown in culture as described in (Malin et al. 2007 were excluded from our image analyses, and the total neurite length was normalized by a 204 number of cell bodies in each image thus producing a value of neurite length per neuron. Table 2 demonstrate that 217 diabetic mice at the end of the study weighed significantly more than control mice and non-218 fasting blood glucose and hemoglobin A 1 C levels were significantly elevated. Treating diabetic 219 mice with a dietary enrichment of menhaden oil or daily injections of resolvin D1 for the final 6 220 weeks of the experimental period did not affect weight gain, elevated blood glucose levels or 221 hemoglobin A 1 C levels. Diabetic mice were insulin resistant as shown by impaired glucose 222 clearance and treating diabetic mice with a dietary enrichment of menhaden oil or with 223 exogenous resolvin D1 did not improve glucose clearance (Figure 1 ). Serum triglycerides and 224 free fatty acid levels were similar in control and diabetic mice. However, diabetic mice had a 225 significant increase in serum free cholesterol levels compared to control mice, which was not 226 corrected by treatments. Serum resolvin D1 levels were determined by EIA (Figure 2) . 227
Resolvin D1 levels were significantly increased in serum from diabetic mice treated with a diet 228 enriched with menhaden oil compared to control mice, untreated diabetic mice and diabetic 229 mice treated exogenously with resolvin D1. Liver proteasome activity was decreased in diabetic 230 mice and was partially improved by dietary enrichment with menhaden oil but not resolvin D1 231 treatments (Table 2 ). Decreased liver proteasome activity is a marker for endoplasmic 232 reticulum stress (Otoda et al. 2013 ). Liver steatosis (fatty liver) was significantly increased in 233 diabetic mice (Table 2) . Treating diabetic mice with a diet enriched with menhaden oil and to a 234 greater extent with daily injections of resolvin D1 reduced liver steatosis. 235
Effect of dietary treatment with menhaden oil or exogenous resolvin D1 of mice fed a high 236
fat diet and treated with low dosage of streptozotocin on nerve conduction velocity, thermal 237 nociception and intraepidermal nerve fiber density. Motor and sensory nerve conduction 238 velocities were significantly decreased in diabetic mice (Table 3) . Dietary treatment of diabeticmice with menhaden oil significantly improved motor and sensory nerve conduction velocity 240 although motor nerve conduction velocity in diabetic mice treated with menhaden oil remained 241 significantly slower compared to control mice. Treating diabetic mice with daily injections of 242 resolvin D1 significantly improved both motor and sensory nerve conduction velocity and there 243 was no statistical difference in nerve conduction velocity between control and diabetic mice 244 treated with resolvin D1. Latency to a thermal stimulus was significantly increased in diabetic 245 mice compared to control mice. Dietary enrichment of menhaden oil or exogenous resolvin D1 246 treatment reduced the increase in latency to thermal stimulus as compared to untreated diabetic 247 mice, such that there is no longer a significant difference when compared to controls (Table 3) . 248
Intraepidermal nerve fiber density of the skin from the hindpaw was significantly decreased in 249 diabetic mice ( Figure 3 ). Dietary enrichment with menhaden oil or daily treatments with resolvin 250 D1 for the final 6 weeks of the study period at minimum slowed the loss of these nerves, such 251 that intraepidermal nerve fiber density in treated diabetic mice was significantly greater than in 252 untreated diabetic mice. However, treatment for 6 weeks did not fully restore intraepidermal 253 nerve fiber density since intraepidermal nerve fiber density in treated mice remained 254 significantly decreased compared to controls. 255
Effect of dietary treatment with menhaden oil or exogenous resolvin D1 of mice fed a high 256
fat diet and treated with low dosage of streptozotocin on sub-epithelial and epithelial corneal 257 nerve fibers. Corneal confocal microscopy, a noninvasive in vivo imaging procedure that can be 258 Figure 6 demonstrate that corneal nerves penetrating the epithelial layer of the 284 cornea are also decreased in diabetic mice. Diabetic mice treated with a daily injection of 285 resolvin D1 had a significantly improved innervation of the corneal epithelium compared to 286 untreated diabetic mice. Treating diabetic mice with a diet enriched with menhaden oil also 287 tended to reduce the loss of corneal nerves penetrating the epithelium but these results were 288 not significantly different from untreated diabetic mice. In both menhaden oil and resolvin D1 289 treated diabetic mice loss of corneal nerves penetrating the epithelium remained significantly 290 decreased compared to control mice. 291
Effect of dietary treatment with menhaden oil or exogenous resolvin D1 of mice fed a high 292 fat diet and treated with low dosage of streptozotocin on retinal ganglion cell complex thickness. 293
We previously reported a significant thinning of the retinal ganglion cell complex in mice models 294 of type 1 and type 2 diabetes compared to control mice (Yorek et al. 2015) . In this study we 295 demonstrated that treating a mouse model of type 2 diabetes with a diet enriched with 296 menhaden oil or with daily injections of resolvin D1 completely prevented the thinning of the 297 retinal ganglion cell complex observed in untreated diabetic mice after 22 weeks of a high fat 298 diet and 14 weeks of hyperglycemia (Figure 7) . reported that n-3 fatty acids promote neurite outgrowth from dorsal root ganglia neurons. 303
However, it is unknown whether resolvins can increase neurite outgrowth. Data in Figure 8  304 demonstrates that a 24h incubation with 50 nM resolvin D1 increases neurite outgrowth from 305 dorsal root ganglia neurons by about 2-fold. In a separate study resolvin D1 increased neurite 306 outgrowth by primary cultures of trigeminal ganglia from adult mice by about 2.5-fold (data not 307 shown). 308
DISCUSSION 310
Menhaden oil is derived from the Menhaden, a forage fish of the genera Brevoortia 311
Ethmidium that resides in Atlantic, Pacific and Gulf waters. Oil prepared from these fish is 312 commonly used as a source for omega-3 (n- exogenous resolvin D1 through a daily i.p. injection reversed deficits of some diabetic 359 neuropathy endpoints and hepatic steatosis and at the very least slowed progression of loss of 360 sensory nerves in the skin and cornea. Furthermore, the benefits observed with exogenousresolvin administration were similar or greater than the effects obtained by dietary 362 supplementation of diabetic mice with menhaden oil. It is important to stress that the study 363 design used was an intervention. The mice had been on a high fat diet for 16 weeks with 8 364 weeks of hyperglycemia prior to the 6 week treatment phase. Resolvin D1 also promoted 365 neurite growth by cultured dorsal root ganglion neurons suggesting a direct effect by resolvins 366 on neuron generation. 367
In our studies hepatic steatosis was improved to a greater extent by exogenous resolvin D1 368 treatment than dietary enrichment with menhaden oil. This could be due to exogenous 369 treatment with resolvin D1 being more efficacious than resolvins produced endogenously from 370 menhaden oil. A daily injection of resolvin D1 could have a more robust effect on signaling 371 pathways in the liver and resolving inflammatory conditions contributing to hepatic steatosis. 372
Our assay for resolvin D1 in serum indicated that daily treatment with resolvin D1 did not cause 373 an increase in resolvin D1 levels compared to control or untreated diabetic mice. This is not 374 surprising since collection of serum occurred 24 hours after the final injection of resolvin D1. It 375 is also important to stress that induction of diabetes does not appear to decrease resolvin D1 376 production. This suggests that the expression and activity of enzymes responsible for 377 production of resolvins such as 15-lipoxygenase-1 are not compromised by diabetes. 378 Improvement in hepatic steatosis occurred even though serum cholesterol and liver proteasome 379 activity, a marker for endoplasmic reticulum stress, were not restored to control level following 380 dietary treatment with menhaden oil or daily treatment with resolvin D1. This contrasts with a 381 study by Jelinek et al. (2013) that showed that mice fed a high fat diet supplemented with fish oil 382 improved metabolic features as well as glucose tolerance and hepatic steatosis. However, the 383 former study used a prevention design whereas we performed an intervention protocol. injections of resolvin D1 was initiated 8 weeks after the onset of hyperglycemia and motor nerve 398 conduction velocity was significantly improved and sensory nerve conduction velocity was 399 completely corrected after 6 weeks of treatment. This indicates that dietary treatment with 400 menhaden oil or exogenous treatment with resolvin D1 was able to reverse the diabetes-401 induced deficits in nerve conduction velocity. However, it was observed that treatment with 402 menhaden oil or resolvin D1 was more effective in improving sensory nerve conduction velocity 403 than motor nerve conduction velocity. This may be due to different mechanisms contributing to 404 the slowing of motor and sensory nerve conduction velocities. It has been our experience that 405 feeding rodents a high fat diet reduces sensory nerve conduction velocity but not motor nerve 406 with the onset of hyperglycemia that occurs after treating high fat fed rodents with a low dose of 408 streptozotocin there is a decrease in motor nerve conduction velocity. This suggests to us that 409 pathological mechanisms associated with hyperglycemia are responsible for slowing of motor 410 nerve conduction velocity and that menhaden oil or resolvin D1 are not entirely protective 411 against these mechanisms. Treatment of diabetic mice also resulted in inconsistencies 412 between treated and untreated diabetic mice in thermal nociception, intraepidermal nerve fiber 413 density, corneal nerve fiber length and density in the sub-basal layer of the cornea and corneal 414 epithelium and retinal ganglion cell complex thickness. Treatment of diabetic mice with 415 menhaden oil or resolvin D1 appeared to be more effective in protecting thermal nociception 416 than skin intraepidermal nerve fiber density with the latter remaining significantly decreased 417 compared to control mice after 6 weeks of treatment. This may be due to the sensitivity of mice 418 to thermal nociception. It may not be necessary to repair or regenerate fully sensory nerves in 419 the skin in order to have normal thermal nociception. However, these deficits take longer to 420 develop and reach significance compared to slowing of nerve conduction velocities. Given the 421 study design used we can only conclude that following 16 weeks of a high fat diet combined 422 with 8 weeks of untreated hyperglycemia dietary enrichment with menhaden oil or a daily 423 injection of resolvin D1 for 6 weeks slows progression of changes in the density and sensitivity 424 of sensory nerves in the skin, cornea and retinal ganglion cell complex. Future studies will need 425 to examine the effect of intervention after 20 weeks of a high fat diet and 12 weeks of untreated 426 hyperglycemia, after significant changes in nerve density of the skin, cornea and retina have 427 occurred, to determine whether treatment with menhaden oil or resolvin D1 can stimulate nerve 428 regeneration and repair (Yorek et al. 2015) . However, our studies did demonstrate that 429 exogenous resolvin D1 stimulates neurite outgrowth from dorsal root ganglion neurons isolated 430 from normal C57Bl/J mice. These results are similar to studies demonstrating regeneration of The number of mice in each group was the same as shown in Table 2 . *** p < 0.001 compared Control (3) 15 ± 2 2 ± 1 6 ± 1 21 ± 3 47 ± 4 1 ± 1 < 1
High fat (3) 17 ± 2 2 ± 1 10 ± 2 37 ± 4 29 ± 4 < 1 < 1
Menhaden oil enriched high fat (3)
18 ± 2 8 ± 1 6 ± 1 21 ± 3 15 ± 2 9 ± 1 8 ± 1
Data are presented as the mean ± S.E.M. 16:0, palmitic acid; 16:1, palmitoleic acid; 18:0, stearic 692 acid; 18:1, oleic acid; 18:2, linoleic acid; 20:5, eicosapentaenoic acid; 22:6, docosahexaenoic acid.
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Parentheses indicate the number of experimental determinations. 
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